Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | CRHBP | P24387 | 2/20 | 0.61 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.61 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | CDC25C | P30307 | 3/20 | 0.57 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7596877 | 1.00 | ALDH1A1 (0.63) | ALDH1A1CRHBPCRHR2SIGMAR1TMEM97 | |
| SCHEMBL3143117 | 0.94 | KCNH2 (0.64) | ALDH1A1CRHBPCRHR2SIGMAR1TMEM97 | |
| SCHEMBL3143221 | 0.89 | CRHBP (0.71) | ALDH1A1CRHBPCRHR2SIGMAR1TMEM97 | |
| SCHEMBL3156945 | 0.87 | KCNH2 (0.57) | ALDH1A1CRHBPCRHR2SIGMAR1TMEM97 | |
| SCHEMBL9628028 | 0.85 | KCNH2 (0.74) | CRHBPCRHR2SIGMAR1KCNH2CDC25C | |
| SCHEMBL3257916 | 0.85 | POLB (0.58) | ALDH1A1CRHBPCRHR2SIGMAR1TMEM97 | |
| SCHEMBL3157345 | 0.84 | ALDH1A1 (0.57) | ALDH1A1CRHBPCRHR2SIGMAR1KCNH2 | |
| SCHEMBL17539702 | 0.82 | CYP1A2 (0.62) | ALDH1A1CRHBPCRHR2KCNH2PKM | |
| SCHEMBL8402960 | 0.82 | SIGMAR1 (0.71) | ALDH1A1SIGMAR1PYCR1MEN1KMT2A | |
| SCHEMBL3151107 | 0.81 | KDM4E (0.67) | ALDH1A1CRHBPCRHR2SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224170-B9 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2157081-A1 | Indolinones substituted in six locations, their manufacture and their application as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2010-02-24 | — | — | EP | disclosed |
| EP-1224170-B1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-08-12 | — | — | EP | disclosed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | disclosed |
| US-20030138846-A1 | Solid phase supports | AKZO NOBEL N.V. (NL) | 2003-07-24 | — | — | US | disclosed |
| US-6545035-B1 | Having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-08 | — | — | US | disclosed |
| CN-1391557-A | 6-substituted indolinones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-01-15 | — | — | CN | disclosed |
| US-6486354-B1 | Solid phase supports | AKZO NOBEL N.V. (NL) | 2002-11-26 | — | — | US | disclosed |
| EP-1224170-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma KG (DE) | 2002-07-24 | — | — | EP | disclosed |
| US-6319918-B1 | FOR LYMPHOMA OR SOLID TUMORS TREATMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-11-20 | — | — | US | disclosed |
| EP-1100779-A1 | SUBSTITUTED INDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 2001-05-23 | — | — | EP | disclosed |
| WO-2001027081-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000073297-A1 | SUBSTITUTED INDOLINONE AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-12-07 | — | — | WO | disclosed |
| WO-1999062882-A1 | SUBSTITUTED INDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999009073-A1 | SOLID PHASE SUPPORTS | AKZO NOBEL N.V. (NL) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138846-A1 | Solid phase supports | NES, CCNY, CCNA2 | ALDH1A1 1873/4885CRHBP 1856/4885CRHR2 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.